2004 FDA approves Sensipar (cinacalcet HCl) for the treatment of secondary hyper-parathyroidism in chronic kidney disease patients on dialysis and for the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma FDA ...
FDA approves Sensipar (cinacalcet HCl) for the treatment of secondary hyper-parathyroidism in chronic kidney disease patients on dialysis and for the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma
FDA approves Enbrel for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy
2003
FDA approves Enbrel for the treatment of ankylosing spondylitis and other expanded indications
2002
FDA approves Enbrel to treat the signs and symptoms of active arthritis in patients with psoriatic arthritis
FDA approves Neulasta to decrease the incidence of infection in patients with non-myeloid cancers receiving myelosuppressive chemotherapy
Amgen completes Immunex acquisition
FDA approves Aranesp for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies
FDA approves Amgen's Rhode Island manufacturing facility for Enbrel
2001
FDA approves Kineret to treat the signs and symptoms in patients with moderately to severely active rheumatoid arthritis whose disease has failed to respond to one or more disease-modifying medicines
Kevin W. Sharer named chairman
FDA approves Aranesp to treat anemia associated with chronic renal failure, including patients on dialysis and not on dialysis
2000
Kevin Sharer named CEO
Amgen acquires Kinetix Pharmaceuticals
1999
Gordon M. Binder retires
Amgen reaches sales of more than $3 billion
FDA approves Enbrel to treat patients with moderately to severely active polyarticular-course juvenile rheumatoid arthritis whose disease has failed to respond to prior disease-modifying medicines
1998
FDA approves Neupogen for use in support of treatment of acute myeloid leukemia
FDA approves Enbrel to treat patients with rheumatoid arthritis whose disease has failed to respond to prior disease-modifying medicines
1997
FDA approves Infergen for treating patients with Hepatitis C
1996
FDA approves Epogen for reduction of allogeneic blood transfusion in surgery patients
Amgen reaches sales of more than $2 billion
1995
FDA approves Neupogen for use in peripheral blood progenitor cell transplants
1994
FDA approves Neupogen for patients undergoing bone marrow transplantation and for patients with severe chronic neutropenia
Amgen receives U.S. Dept. of Commerce National Medal of Technology
Amgen completes acquisition of Synergen
1993
FDA approves Epogen for treatment of anemia in cancer patients on chemotherapy
1992
Kevin W. Sharer elected President and COO
Amgen reaches sales of more than $1 billion
Amgen added to the S&P 500
1991
FDA approves Neupogen to decrease the incidence of infection associated with chemotherapy-induced neutropenia in patients with non-myeloid cancers receiving myelosuppressive therapy
Amgen establishes the Amgen Foundation for charitable giving
Neupogen named "Product of the Year" by Fortune magazine
1990
George B. Rathmann retires
Gordon M. Binder elected Chairman of Amgen's Board of Directors
1989
Immunex clones TNF receptor, later patented and named Enbrel
Amgen receives first U.S. patent for recombinant G-CSF Neupogen
FDA approves Epogen for the treatment of anemia in patients with end-stage renal disease
Epogen named "Product of the Year" by Fortune magazine
Amgen added to the NASDAQ 100 Index
1988
Gordon M. Binder elected CEO
1987
Company changes name to Amgen Inc. and becomes a Delaware corporation
Amgen receives first patent on DNA used in producing Epogen
1986
George B. Rathmann elected chairman of Amgen's board of directors
1985
Larry M. Souza's team clones granulocyte colony-stimulating factor (G-CSF), later patented and named Neupogen
1983
Company changes name to Amgen
A team led by Fu-Kuen Lin clones erythropoietin, later patented and named Epogen
IPO of 2,350,000 shares at $18 per share results in $40 million raised; ticker symbol: AMGN
1981
Company changes name to Applied Molecular Genetics Inc.
1980
Venture capitalists Bill Bowes, Franklin "Pitch" Johnson, Sam Wohlsteadter and Raymond Baddour establish AMGen (Applied Molecular Genetics Inc.) as a California corporation on April 8
